model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT02542410,NCT02542410,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].id,EV,EV,,132882,,,,SecondaryId,protocolSection.identificationModule.secondaryIdInfos.id,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].type,EV,EV,,FDA,,,,SecondaryIdType,protocolSection.identificationModule.secondaryIdInfos.type,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].domain,EV,EV,,Food and Drug Administration,,,,SecondaryIdDomain,protocolSection.identificationModule.secondaryIdInfos.domain,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,FN,FN,Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study,,False,0.0,,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study,"Efficacy and safety of a novel nonhormonal therapeutic agent, cabergoline, compared with that of the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in young women with endometriosis",True,0.86,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,"The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis.","This randomized, double-blind, placebo-controlled pilot study aims to estimate the efficacy and safety of cabergoline, a novel nonhormonal therapeutic agent, compared with the standard clinical therapy, norethindrone acetate (NETA), for the treatment of endometriosis-associated pain in young women. The study hypothesizes that cabergoline will inhibit endometriosis-mediated neuroangiogenesis, leading to decreased pain measures, improved functional disability scores, and decreased circulating angiogenic and inflammatory biomarkers.",True,0.96,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,EV,EV,,"Endometriosis is a chronic condition where the growth of lesions requires angiogenesis. While hormonal therapies like NETA are standard, they often have limitations regarding side effects and recurrence. This study investigates cabergoline, a dopamine receptor 2 (DRD2) agonist, which functions as an inhibitor of the vascular endothelial growth factor (VEGF) pathway, offering a potential nonhormonal treatment option.

Participants included premenopausal women aged 15–40 years with surgically confirmed endometriosis and reported pelvic pain. They were randomized to receive either oral NETA (5 mg/day) combined with a placebo twice weekly, or oral cabergoline (0.5 mg) twice weekly combined with a placebo daily for a duration of 6 months.

The primary outcome measure was the assessment of pain using the Brief Pain Inventory (BPI) interference scale and a Visual Analog Scale (VAS) for pain intensity. Secondary measures included the Beck Depression Inventory-II for emotional functioning, the Functional Disability Inventory, and the patient global impression of change. Additionally, serum samples were analyzed for angiogenic and inflammatory biomarkers, including VEGF-R1, TNF-alpha, and IL-8. Safety was monitored through adverse event reporting and laboratory parameters such as liver function tests and lipid panels.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,TP,['Endometriosis'],"['Endometriosis', 'Chronic Pelvic Pain', 'Endometriosis-associated Pain']",True,1.0,superset,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,EV,EV,,"['Cabergoline', 'Norethindrone Acetate', 'NETA', 'Angiogenesis', 'VEGF Pathway Inhibitor', 'Dopamine Receptor 2 Agonist', 'Nonhormonal Therapy']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,TP,FP,['PHASE2'],['NA'],False,0.0,disjoint,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,QUADRUPLE,DOUBLE,True,0.7,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"All the medications were dispensed by the research pharmacy in a gelatin capsule and were identical in appearance. The principal investigator, study staff, and participants remained blinded to the treatment assignment throughout the 6-month study.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,TP,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']","['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']",True,0.75,partial,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,10,9,True,0.9,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[2].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[2].name,EV,EV,,Placebo (twice weekly),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,Placebo (daily),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[0].description,EV,EV,,0.5 mg orally twice weekly.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[1].description,EV,EV,,5 mg/day orally.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[2].description,EV,EV,,Placebo tablet taken twice weekly to match the Cabergoline dosing schedule.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,Placebo tablet taken daily to match the NETA dosing schedule.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[2].armGroupLabels,EV,EV,,['NETA Group'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,['Cabergoline Group'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].measure,EV,EV,,Emotional Functioning (Beck Depression Inventory-II),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].measure,EV,EV,,Patient Global Impression of Change Scale,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].measure,EV,EV,,Serum Angiogenic and Inflammatory Biomarkers,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].measure,EV,EV,,Urinary Marker of Oxidative Stress,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].measure,EV,EV,,Adverse Events,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[7].measure,EV,EV,,Safety Laboratory Parameters,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].description,EV,EV,,"Measured using the Beck Depression Inventory-II, with scores categorized as follows: <10, minimal or no depression; 10–18, mild to moderate; 19–29, moderate to severe; and 30–63, severe depression.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].description,EV,EV,,"A 7-point rating scale asking: 'Since beginning this study, how would you describe the change (if any) in activity limitations, symptoms, emotions, and overall quality of life?' Scores categorized as: 1–3 (no/minimal change), 4–5 (moderate improvement), and 6–7 (definite/considerable improvement).",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].description,EV,EV,,"Measurement of inflammation and angiogenic pathway markers including VEGF, TNF-α, placental growth factor, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, VEGF receptor 1 (VEGF-R1), monocyte chemotactic protein-1, interleukin 8 (IL-8), E-selectin, and IL-1β.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].description,EV,EV,,"Assessment of 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) in urine samples.",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].description,EV,EV,,"Adverse effects experienced during treatment, graded using the Common Terminology Criteria for Adverse Events (CTCAE, v5.8).",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[7].description,EV,EV,,"Measurement of serum hemoglobin A1c levels, erythrocyte sedimentation rate, serum creatinine levels, lipid panels, and liver function tests (aspartate transaminase, alanine aminotransferase, total bilirubin).",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[1].timeFrame,EV,EV,,"Baseline, 3 months, and 6 months",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[2].timeFrame,EV,EV,,"Baseline, 3 months, and 6 months",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[4].timeFrame,EV,EV,,"Baseline, 3 months, and 6 months",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[5].timeFrame,EV,EV,,"Baseline, 3 months, and 6 months",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[6].timeFrame,EV,EV,,Up to 6 months,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.secondaryOutcomes[7].timeFrame,EV,EV,,"Baseline, 3 months, and 6 months",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Surgically confirmed endometriosis
* Age between 15-40 y, and premenopausal
* Pelvic pain score ≥3 on a Visual Analog Scaleover the last month

Exclusion Criteria:

* Use of other concurrent hormone medications (such as birth control pills)
* Impaired liver function (ALT \> 2x normal) or liver disease (cirrhosis, hepatitis)
* Pregnancy
* Breast cancer
* Active thromboembolic disease
* Uncontrolled hypertension, history of cardiac valve disorder, history of fibrotic disorders","Inclusion Criteria:
* Aged 15–40 years
* Premenopausal
* Surgically confirmed endometriosis, determined using laparoscopy within 2 years prior to study baseline
* Experiencing pelvic pain over the last month, as determined using a visual analog scale (VAS) score of ≥3

Exclusion Criteria:
* Using other hormonal medications (such as combined oral contraceptive pills)
* Thrombotic disease
* Contraindications to the study medications (impaired liver function, breast cancer, cardiac valvular disorders, etc.)",True,0.96,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,FEMALE,FEMALE,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,TP,15 Years,15 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,TP,TP,40 Years,40 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,"['CHILD', 'ADULT']","['CHILD', 'ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
